Outcomes after SIT

CharacteristicsFailed steroid tapering after SITIMC recurrence
OR (95% CI)POR (95% CI)P
ICI type
Anti-PD-1/L1 monotherapyReferenceReference
Anti-CTLA-4 therapy0.50 (0.19–1.29)0.1501.09 (0.36–3.37)0.871
Colitis grade
1–2ReferenceReference
3–44.09 (1.53–10.98)0.0051.79 (0.59–3.38)0.299
Multiple hospitalizations9.05 (2.79–29.33)< 0.00126.25 (3.22–213.82)0.002
Failed steroid tapering before SIT3.75 (1.39–10.16)0.0092.42 (0.75–7.77)0.138
Failed steroid tapering after SIT4.07 (1.29–12.88)0.017
Type of SIT
VedolizumabReferenceReference
Infliximab0.47 (0.18–1.22)0.12012.57 (1.57–100.57)0.017
No. of SIT infusions
1–2ReferenceReference
≥32.97 (1.13–7.79)0.0270.09 (0.01–0.72)0.023
Endoscopic remission1.68 (0.41–6.96)0.4740.15 (0.03–0.79)0.025
Histologic remission0.67 (0.18–2.46)0.5430.18 (0.04–0.88)0.033
Number of steroids tapering attempts9.50 (3.76–24.01)< 0.0013.35 (1.68–6.69)0.001
Duration from IMC onset to SIT1.05 (1.01–1.09)0.0111.00 (0.98–1.03)0.774
Overall duration of steroids1.02 (1.01–1.04)0.0011.01 (1.00–1.03)0.022
Calprotectin at time of onset1.00 (0.99–1.00)0.5991.00 (0.99–1.01)0.346
Calprotectin after SIT1.00 (0.99–1.00)0.5731.01 (1.00–1.01)0.014
Duration of hospitalization1.12 (1.04–1.21)0.0041.14 (1.05–1.23)0.001
Duration of symptoms1.06 (1.03–1.08)< 0.0011.02 (1.01–1.03)0.008

Abbreviations: CI, confidence interval; CTLA, cytotoxic T lymphocyte associated protein; SIT, selective immunosuppressive therapy; OR, odds ratio; PD-1, programmed death protein 1; PD-L1, PD-1 ligand